{"id":"W3122132687","doi":"10.1007/s13555-021-00490-3","title":"Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Psoriasis Area and Severity Index; Adverse effect; Internal medicine; Ustekinumab; Plaque psoriasis; Open label; Randomized controlled trial; Clinical trial; Dermatology; Gastroenterology; Disease; Adalimumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003969456,0.0008346949,0.001452789,0.0001832857,0.0002995198,0.0008897141,0.0003992844,0.0009545839,0.002369909],"category_scores_gemma":[0.002006828,0.0002998475,0.001311543,0.0002533438,0.0005207962,0.0006342576,0.0003492256,0.001810638,0.0006042614],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003491277,"about_ca_system_score_gemma":0.0009649437,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002841281,"about_ca_topic_score_gemma":0.0006636432,"domain_scores_codex":[0.9989682,0.0006014623,0.0000843698,0.0001235845,0.0001169718,0.0001055002],"domain_scores_gemma":[0.998276,0.0004429641,0.0004701859,0.0001468265,0.0001638824,0.0005001777],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8684694,0.02615121,0.01684275,0.001158438,0.001999384,0.0001760646,0.0002649628,0.000600769,0.01017765,0.0001234836,0.002914733,0.07112115],"study_design_scores_gemma":[0.7253224,0.2265624,0.04220216,0.0001122475,0.0009103238,0.0003245779,0.00005346095,0.0006395427,0.001100949,0.0001624373,0.002573225,0.00003631157],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924172,0.003265416,0.0003052123,0.0003309669,0.00008378615,0.001260069,0.0008731338,0.00004262463,0.001421629],"genre_scores_gemma":[0.9920284,0.001724986,0.0009038172,0.0008378976,0.0002515838,0.001535637,0.001740352,0.000009966914,0.0009675215],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003969456,"threshold_uncertainty_score":0.02099276,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02387485861242551,"score_gpt":0.2783510814867329,"score_spread":0.2544762228743074,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}